Bayer Confirms 2025 Financial Outlook Amid Market Challenges

Bayer AG has confirmed its upgraded full-year 2025 Group guidance following solid business performance in the first nine months of the year. The company reported resilience in its agricultural and pharmaceuticals divisions, with the Pharmaceuticals Division maintaining strong topline results. However, Bayer noted that its Consumer Health division is facing an increasingly challenging market environment. The company now projects currency- and portfolio-adjusted sales growth for Consumer Health at minus 1 to plus 1 percent, a revision from the previous expectation of growth at the lower end of the 2 to 5 percent range. Despite these challenges, Bayer does not anticipate any impact on the division’s EBITDA margin before special items. Additionally, due to increased allocations to litigation provisions, the company now expects special items in full-year Group EBITDA to be between minus 4.0 to minus 3.5 billion euros, compared to the previous forecast of minus 3.5 to minus 2.5 billion euros. Special items in full-year Group EBIT are now expected to be between minus 3.0 to minus 2.5 billion euros, revised from the earlier range of minus 2.5 to minus 1.5 billion euros. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here